Eli Lilly's experimental obesity drug retatrutide has cleared a major clinical trial, with participants losing an average of 85 pounds, the company announced Wednesday. The results represent a notable advance beyond existing GLP-1 medications such as Ozempic and Mounjaro, which have already reshaped the weight loss drug market in recent years.

Retatrutide works by targeting three hormonal receptors simultaneously — GIP, GLP-1, and glucagon — a triple-agonist mechanism that researchers believe may account for the drug's outsized weight loss results compared to existing dual-agonist therapies. The trial results were released by Eli Lilly ahead of a formal peer-reviewed publication.

The announcement comes amid a surging broader market for peptide-based weight loss compounds. The FDA is facing mounting pressure from patients, physicians, and industry groups to clarify regulatory pathways and ease access to a range of peptide therapies that have proliferated in the wake of GLP-1 popularity. Compounding pharmacies and online clinics have expanded rapidly to meet demand, raising safety and oversight concerns.

Analysts expect Eli Lilly to pursue FDA approval for retatrutide, though a timeline has not been formally announced. The drug would enter a competitive landscape that already includes Novo Nordisk's semaglutide and Lilly's own tirzepatide. If approved, retatrutide could further shift clinical standards for obesity treatment, a condition affecting more than 40 percent of American adults.